It could have been even worse

13/02/20 -"Clariant reported a conciliatory ending after a challenging and bumpy 2019. But it happened in more than ‘just’ some businesses. With the management adjustments, two former members of the ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

13/02/20

Download

You may also be interested by these reports :

12/11/26

Brenntag

Brenntag’s CMD introduced a new medium-term framework targeting growth above the chemical market, a ~10% operating EBITDA margin and ROIC above 12%. ...

11/11/26

Brenntag

Brenntag’s Q3 sales beat consensus by 6.6%, supported by higher chemical prices and favourable FX. However, operating EBITDA was broadly in line with ...

11/11/26

KWS SAAT SE & Co. KGaA

1Q26/27: All in all, a solid start – FY26/27E guidance confirmed

10/11/26

K+S

K+S’s Q3 2026 sales growth was driven by price and mix, not volume, as the Bethune shutdown hit volumes. De-icing refill demand lifted Industry+. ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue